Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inhibitor
NLRP3-IN-66 is a selective inhibitor of the NLRP3 inflammasome, which plays a crucial role in the activation of inflammatory responses. This compound demonstrates significant biological activity by reducing the production of pro-inflammatory cytokines, making it a valuable tool for research in inflammatory diseases. NLRP3-IN-66 is essential for studies targeting the modulation of the NLRP3 pathway in both in vitro and in vivo models. -
NLRP3 Modulator
NLRP3 Modulator 1 is a selective modulator targeting the NLRP3 inflammasome. This compound functions as an agonist or partial agonist, effectively enhancing NLRP3 activity. It is valuable for research into conditions, diseases, or disorders where reduced NLRP3 activity plays a role in disease pathology, facilitating studies on inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-61 is a potent inhibitor of NLRP3, targeting the NLRP3 inflammasome pathway. This compound effectively inhibits pyroptosis in THP-1 cells with an IC50 value of 12.6 nM and reduces IL-1β release with an IC50 of 25.3 nM. NLRP3-IN-61 is suitable for research applications investigating inflammatory responses and therapeutic interventions in diseases associated with the NLRP3 inflammasome. -
NLRP3/URAT1 Inhibitor
NLRP3/URAT1-IN-1 is an orally active dual inhibitor targeting NLRP3 and URAT1, with an IC50 of 3.81 μM. This compound effectively inhibits IL-1β release in LPS- and ATP-stimulated mouse bone marrow-derived macrophages, demonstrating an IC50 of 2.61 μM. In vivo studies reveal that NLRP3/URAT1-IN-1 significantly reduces serum uric acid levels and mitigates liver and kidney damage in models of acute hyperuricemia. This reagent is essential for investigating the pathophysiology of gout and hyperuricemia. -
NOD-like Receptor (NLR) Inhibitor
Apilimod hydrochloride is an inhibitor of the PIKFYVE kinase, targeting the NOD-like receptor (NLR) pathway. This compound facilitates the activation of NLRP3 inflammatory vesicles and promotes the secretion of IL-1β. Its ability to inhibit host cell proteases may prevent viral invasion; however, it may also obstruct antiviral immune responses, which could lead to increased immunosuppression in conditions such as COVID-19. Research applications include studies on inflammation, immune response regulation, and viral pathogenesis. -
NLRP3 Degrader
MC-ND-18 is an ATTEC degrader targeting NLRP3, functioning primarily through autophagic pathways. With a DC50 value of 125.5 nM in THP-1 cells, this compound facilitates the selective degradation of NLRP3. Composed of a ligand specific to NLRP3, a linker, and an LC3 ligand, MC-ND-18 is valuable for research investigating inflammation and diseases associated with NLRP3 activation. -
NLRP3 Inflammasome Inhibitor
YM-I-26 is a selective inhibitor of the NLRP3 inflammasome, effectively modulating inflammatory responses. It enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells while concurrently inhibiting the secretion of pro-inflammatory cytokines IL-1β and IL-10. This compound is useful for investigating the role of the NLRP3 inflammasome in various inflammatory conditions and its potential as a therapeutic target in immune modulation. -
NLRP3 Inhibitor
Isoandrographolide is a selective inhibitor of the NLRP3 inflammasome, known for its potential to modulate inflammatory responses. This compound exhibits significant hepatoprotective effects and promotes cell differentiation. Research applications include studying the role of NLRP3 in inflammatory diseases and exploring therapeutic strategies for conditions such as silicosis. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-27 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 0.55 μM. This compound is instrumental in investigating the role of NLRP3 in inflammatory processes and immune response modulation. It is a valuable tool for researchers studying the molecular mechanisms of inflammation and potential therapeutic strategies for associated diseases. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-86 is a selective inhibitor of the NLRP3 inflammasome. This compound demonstrates significant potency in reducing lipopolysaccharide (LPS) and Nigericin-induced lactate dehydrogenase release, with IC50 values of 2.69 μM in THP-1 cells and 1.75 μM in J774A.1 cells. Additionally, NLRP3-IN-86 effectively inhibits gasdermin D cleavage and interleukin-1 beta (IL-1β) secretion, thereby mitigating pyroptosis. This reagent is ideally suited for investigations into inflammatory processes and the underlying mechanisms of pyroptotic cell death. -
NLRP3 Inhibitor
NLRP3-IN-8 is a potent inhibitor of the NLRP3 inflammasome, acting through direct binding with an IC50 of 1.23 μM against IL-1β. This compound demonstrates notable metabolic stability, with a half-life of 138.63 minutes in liver microsomes, and exhibits minimal toxicity, as indicated by an IC50 greater than 100 μM against L02 cells. NLRP3-IN-8 is valuable for research into inflammatory disorders and potential therapeutic interventions targeting the NLRP3 pathway. -
NLRP3 Inhibitor
NLRP3-IN-31 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value in the range of 0.3-0.5 μM. This compound effectively modulates the activation of NLRP3, making it a valuable tool for studying inflammatory pathways. NLRP3-IN-31 can be utilized in research focused on autoinflammatory diseases, metabolic disorders, and neuroinflammation, aiding in the understanding of inflammasome-mediated processes. -
NLRP3 Inhibitor
NLRP3-IN-15 is a selective inhibitor of the NLRP3 inflammasome, targeting the pathway responsible for the activation of pro-inflammatory cytokines. With an IC50 of 0.114 μM, NLRP3-IN-15 effectively inhibits the release of IL-1β, a key mediator in inflammatory responses. This compound is suitable for investigating the role of NLRP3 in various inflammatory disorders and related research applications. -
NEK7 Degrader
NEK7 degrader-2 (Compound 25) is a targeted NEK7 degrader that facilitates dose-dependent degradation of NEK7 specifically in human PBMC-derived macrophages. This compound effectively reduces the release of pro-inflammatory cytokine IL-1β triggered by NLRP3 inflammasome activation. NEK7 degrader-2 serves as a valuable tool for investigating the mechanisms underlying inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
NLRP3 Inhibitor
NLRP3-IN-62 is a selective inhibitor of the NLRP3 inflammasome, demonstrated to effectively inhibit pyroptosis in THP-1 cells with an IC50 of 0.7 nM. Additionally, it suppresses the release of interleukin-1 beta (IL-1β) with an IC50 of 108.5 nM. This compound serves as a valuable tool for research in inflammation and immune responses, particularly in studies related to diseases involving pyroptotic cell death. -
NLRP3 Modulator
NLRP3 Modulator 7 is a specific inhibitor of the NLRP3 inflammasome, effectively regulating its activity. This compound demonstrates potent inhibitory effects on interleukin-1 beta (IL-1β) secretion, with an IC50 value of less than 500 nM. NLRP3 Modulator 7 is applicable in research focused on inflammatory diseases and disorders related to the NLRP3 pathway. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-77 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 5.36 nM in suppressing the viability of THP-1 cells. This compound effectively reduces the secretion of pro-inflammatory cytokines, specifically interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is a valuable tool for investigating diseases associated with aberrant NLRP3 inflammasome activation, including various cancers and inflammatory disorders. -
Anti-inflammatory Agent
Macarangin is an anti-inflammatory agent isolated from propolis. It exhibits significant DPPH radical-scavenging activity and demonstrates anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome. This compound is valuable for research applications focused on inflammation pathways and oxidative stress. -
NLRP3 Inhibitor
NLRP3-IN-22 is a selective inhibitor of the NLRP3 inflammasome, demonstrating an inhibition rate of 67% at a concentration of 10 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in various research areas, including immunology and disease models related to chronic inflammation. Its selective inhibition makes it a valuable tool for elucidating the mechanisms underlying NLRP3-mediated pathologies. -
NLRP3 Inhibitor
Selnoflast monopotassium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively inhibits IL-1β release induced by NLRP3 activation in monocyte-derived macrophages from individuals with Alzheimer's disease. This compound shows significant promise for research applications related to Alzheimer's disease and other systemic inflammatory disorders, including ulcerative colitis and chronic obstructive pulmonary disease. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-38 is a selective inhibitor of the NOD-like receptor protein 3 (NLRP3), known for its role in mediating inflammatory responses through inflammasome activation. With an EC50 value of 23 nM, it effectively reduces the activation of the NLRP3 inflammasome, making it a valuable tool for research into inflammatory diseases. This compound is suited for studies evaluating the modulation of NLRP3-related signaling pathways and the development of therapeutic strategies targeting NLRP3-mediated inflammation. -
NLRP3 Inhibitor
NLRP3-IN-82 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 5 nM. This compound demonstrates significant biological activity in the modulation of inflammatory pathways and is applicable in research focused on neurological diseases such as Alzheimer's disease, inflammatory conditions like inflammatory bowel disease, and metabolic disorders including obesity. Its selective inhibition of NLRP3 makes it a valuable tool for studying the underlying mechanisms of these pathologies. -
NLRP3 Inhibitor
NLRP3-IN-14 is a selective inhibitor of the NLRP3 inflammasome, exhibiting a binding affinity (KD) of 5.87 μM. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), with an IC50 value of 0.131 μM. NLRP3-IN-14 is valuable for research into inflammatory processes and the development of therapeutics targeting NLRP3-associated diseases. -
NLRP3 Inhibitor
NLRP3-IN-34 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation and downstream signaling. It effectively inhibits reactive oxygen species (ROS) production and interleukin-1 beta (IL-1β) release, exhibiting an IC50 of 0.48 μM in J774A.1 cells. Additionally, NLRP3-IN-34 has demonstrated the capability to inhibit pyroptosis and exhibits anti-inflammatory effects, particularly in models of dextran sulfate sodium (DSS)-induced peritonitis. This compound is valuable for research focused on inflammation and related disease mechanisms. -
NLRP3 Inhibitor
NLRP3-IN-26 is a specific inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.13 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in models of DSS-induced colitis to elucidate its impact on intestinal inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-71 is a selective inhibitor of the NLRP3 inflammasome, demonstrating the ability to inhibit IL-1β secretion. This compound is characterized by its blood-brain barrier permeability and oral bioavailability, making it a valuable tool in the study of neurodegenerative diseases and related inflammatory mechanisms. It offers researchers a practical means to investigate the role of NLRP3 in various neurological disorders. -
NLRP3 Inhibitor
JNJ-79883960 is a potent NLRP3 inhibitor, designed to modulate the NLRP3 inflammasome's activity. This compound has demonstrated efficacy in reducing inflammation, making it a valuable tool for investigating inflammatory pathways and associated diseases. Its application includes research into conditions such as autoimmune disorders and chronic inflammatory diseases, providing insights into potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-65 is a selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune response. This compound exerts significant biological activity by inhibiting the activation of NLRP3, thereby modulating inflammatory responses. It is valuable for research applications related to autoinflammatory diseases, chronic inflammation, and potential therapeutic strategies aimed at controlling NLRP3-mediated pathways. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-4 is a potent inhibitor of the NOD-like receptor (NLR) NLRP3 inflammasome, exhibiting oral bioavailability. This compound is characterized by its ability to mitigate inflammatory processes, making it particularly relevant for research in inflammatory diseases such as colitis. It is a valuable tool for investigating the role of NLRP3 in immune responses and inflammation modulation. -
NLRP3 Inhibitor
NLRP3-IN-64 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an EC50 of 5 nM for the inhibition of NLRP3 activation. This compound is useful for investigating the role of NLRP3 in inflammatory diseases and provides a valuable tool for research in immune response modulation. Its application extends to studying the mechanisms underlying autoinflammatory conditions and potential therapeutic interventions. -
NQO2 Activator
NQO2 activator-1 is a selective activator of NAD(P)H:quinone oxidoreductase 2 (NQO2) that enhances enzymatic activity by 20.89% at a concentration of 10 μM. This compound exhibits a strong inhibitory effect on NLRP3 inflammasome activation, making it a valuable tool for studying inflammation and immunological responses. Research applications include investigations into conditions such as rheumatoid arthritis and other inflammatory disorders. -
NLRP3 Inhibitor
Sebrinoflast is a potent NLRP3 inhibitor, exhibiting an IC50 of ≤1 μM for human NLRP3. This compound is valuable in the study of inflammatory conditions and cardiovascular diseases such as non-alcoholic steatohepatitis (NASH) and atherosclerosis. Additionally, it serves as an important tool in neurological disease research, particularly for Alzheimer's disease. -
NLRX1 Modulator
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA is a modulator of NLRX1, a member of the NLR family involved in the regulation of immune responses. This compound plays a significant role in the study of immune and metabolic disorders, offering insights into potential therapeutic mechanisms. Its unique structure facilitates research into cellular processes related to inflammation and metabolism. -
NLRP3 Inflammasome Inhibitor
NT-0527 is a selective inhibitor of the NLRP3 inflammasome, demonstrating oral bioavailability and effective permeability across the blood-brain barrier. This compound specifically prevents NLRP3 inflammasome formation, leading to decreased maturation and secretion of interleukin-1 beta (IL-1β). NT-0527 exhibits notable anti-inflammatory effects in models of acute inflammation, including the LPS/ATP-induced peritonitis model. It is a valuable tool for research into neuroinflammatory conditions, such as Parkinson's disease and Alzheimer's disease, as well as peripheral inflammatory disorders like type II diabetes and atherosclerosis involving the NLRP3 pathway. -
NOD-like Receptor (NLR) Inhibitor
GSK223 is a quinazolinone compound that acts as a selective inhibitor of the NOD1 pathway. It demonstrates potential anti-inflammatory activity by selectively inhibiting IL-8 release in response to iE-DAP stimulation, while leaving IL-8 secretion unaffected from TNF receptor, TLR2, or NOD2 agonists. Additionally, GSK223 does not directly inhibit RIP2 kinase activity, making it a valuable tool for studying NOD-like receptor signaling and its implications in inflammatory responses. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-53 is a potent inhibitor of the NOD-like receptor NLRP3, exhibiting an IC50 of 3.4 nM. This compound is utilized in research to investigate the roles of the NLRP3 inflammasome in various inflammatory diseases and immune responses. Its selective inhibition helps elucidate the mechanistic pathways involved in NLRP3-related signaling, making it a valuable tool for studying therapeutic targets in the context of autoimmunity and metabolic disorders. -
NLRP3 Inhibitor
NLRP3-IN-58 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 3.85 μM. At a concentration of 10 μM, it effectively reduces IL-1β release by 33%. This compound is valuable for research applications focused on inflammatory pathways and the modulation of innate immune responses. -
NLRP3 Inhibitor
NLRP3-IN-56 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing IL-1β secretion in THP-1 cells with an IC50 of 9.7 nM. This compound serves as a valuable tool for investigating NLRP3-mediated inflammatory responses and associated pathologies. Its ability to modulate IL-1β levels makes it suitable for research into diseases characterized by NLRP3 activation. -
NLRP3 Inhibitor
NLRP3-IN-28 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 0.07 μM in the inhibition of Nigericin-induced pyroptosis. This compound effectively reduces inflammatory responses in vivo, making it a valuable tool for investigating NLRP3-related diseases and inflammatory pathways. Its application in research provides insights into therapeutic strategies targeting inflammasome activation and related inflammatory conditions. -
Inflammasome Inhibitor
3-Et-3TC is a potent inhibitor of the NLRP3 inflammasome, demonstrating its capacity to modulate inflammasome activation. This compound is valuable for investigating the underlying mechanisms of retinal degenerative diseases and other inflammatory conditions. Its structural modification from Lamivudine enhances its efficacy in biochemical research applications targeting inflammasome pathways. -
Gingerol
Diacetoxy-6-gingerdiol is a derivative of gingerol that exhibits anti-inflammatory and antioxidant properties. This compound has been shown to protect the extracellular matrix of nucleus pulposus cells and reduce intervertebral disc degeneration through the inhibition of the IL-1β-mediated NLRP3 pathway. Its research applications include investigating mechanisms of inflammation and extracellular matrix preservation in musculoskeletal disorders. -
NLRP3 inflammasome inhibitor
Isoliquiritigenin is a licorice chalconoid, a type of natural phenols that is currently under experimentation phase testing for use as a cancer treatment as well as an aide for cocaine addiction. -
NLRP3 Activator
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC. -
Endogenous Metabolite
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice. -
TNF Receptor Inhibitor
Muscone, a TNF receptor inhibitor, is derived from the traditional Chinese medicine musk. It effectively inhibits NF-κB signaling and NLRP3 inflammasome activation, resulting in a significant reduction of inflammatory cytokines such as IL-1β, TNF-α, and IL-6. This compound is valuable in research focused on inflammation, cardiac function restoration, and improving survival rates in various pathological conditions. -
GRPR Antagonist
Aurantiamide is a selective antagonist of the Gastrin-Releasing Peptide Receptor (GRPR), demonstrating significant anti-inflammatory and neuroprotective properties. It effectively mitigates inflammation and oxidative stress in renal tissues by targeting GRPR-mediated pathways, including RIPK3/MLKL signaling and NF-κB activation, thereby providing protection against acute kidney injury and promoting endothelial function. Additionally, Aurantiamide inhibits M1 microglial polarization and NLRP3 activation, showcasing efficacy in improving outcomes in Alzheimer's disease mouse models. Its notable in vivo effectiveness extends to various acute kidney injury contexts, including ischemia/reperfusion, sepsis, and hypertension models.
